Replimune Group
REPL
trading on NASDAQ
since 2018
$7.15
(Δ -6.23%
)
-$0.47
since open
Replimune Group is a biopharmaceutical company focused on developing cutting-edge cancer treatments using innovative immunotherapy approaches. **Step-by-Step Explanation:** 1. **Company Name:** Begin with "Replimune Group" as instructed. 2. **Industry Context:** Describe them as a biopharmaceutical company to set the industry context. 3. **Focus Area:** Mention their focus on developing cancer treatments, which is their main product area. 4. **Methodology:** Include that they use immunotherapy approaches to explain their method of treatment development. This sentence effectively conveys the necessary information in a clear and concise manner, adhering to all specified guidelines.
type | open | high | low |
market cap |
volume |
---|---|---|---|---|---|
stock | $6.42 | $8.07 | $5.71 | $291.78M | 202.08M |
eps | p/e | p/s |
operating margin |
profit margin |
yield |
-$0.79 | n/a | +Inf | -Inf% | -Inf% | 0% |